IMMUNOVANT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
IMMUNOVANT, INC. (IMVT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.07 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.07M shares, a 62.34% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 17.99K shares, a 25.55% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 68.49K shares, a 79.82% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.55M shares, a 1450.49% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2026 was 4.47M shares, a 178.54% increase from fiscal 2025.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.61M shares, a 33.04% decline from fiscal 2024.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.40M shares, a 42.53% decline from fiscal 2023.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.17M shares, a 50.27% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.07M shares 10-Q · filed 2026-08-06 | 1.09M shares derived: sum of 2 quarters · filed 2026-08-06 | 1.16M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.70M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 17.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 86.48K shares derived: sum of 2 quarters · filed 2026-05-20 | 1.63M shares derived: sum of 3 quarters · filed 2026-05-20 | 4.47M shares 10-K · filed 2026-05-20 |
| 2025-12-31 | 68.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | 1.62M shares derived: sum of 2 quarters · filed 2026-02-06 | 4.46M shares 10-Q · filed 2026-02-06 | 4.48M shares derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-09-30 | 1.55M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | 4.39M shares 10-Q · filed 2025-11-10 | 4.41M shares derived: sum of 3 quarters · filed 2025-11-10 | 4.75M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 2.84M shares 10-Q · filed 2025-08-11 | 2.86M shares derived: sum of 2 quarters · filed 2025-08-11 | 3.20M shares derived: sum of 3 quarters · filed 2025-08-11 | 3.30M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 24.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | 363.56K shares derived: sum of 2 quarters · filed 2025-05-29 | 463.41K shares derived: sum of 3 quarters · filed 2025-05-29 | 1.61M shares 10-K · filed 2025-05-29 |
| 2024-12-31 | 339.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-06 | 439.25K shares derived: sum of 2 quarters · filed 2025-02-06 | 1.58M shares 10-Q · filed 2025-02-06 | 1.83M shares derived: sum of 4 quarters · filed 2025-02-06 |
| 2024-09-30 | 99.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | 1.24M shares 10-Q · filed 2024-11-07 | 1.49M shares derived: sum of 3 quarters · filed 2024-11-07 | 1.56M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 1.14M shares 10-Q · filed 2024-08-06 | 1.39M shares derived: sum of 2 quarters · filed 2024-08-06 | 1.46M shares derived: sum of 3 quarters · filed 2024-08-06 | 1.51M shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 245.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-29 | 318.00K shares derived: sum of 2 quarters · filed 2024-05-29 | 365.31K shares derived: sum of 3 quarters · filed 2024-05-29 | 2.40M shares 10-K · filed 2024-05-29 |
| 2023-12-31 | 72.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | 119.41K shares derived: sum of 2 quarters · filed 2024-02-12 | 2.15M shares 10-Q · filed 2024-02-12 | 2.70M shares derived: sum of 4 quarters · filed 2024-02-12 |
| 2023-09-30 | 47.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | 2.08M shares 10-Q · filed 2023-11-09 | 2.63M shares derived: sum of 3 quarters · filed 2023-11-09 | 2.88M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 2.03M shares 10-Q · filed 2023-08-10 | 2.58M shares derived: sum of 2 quarters · filed 2023-08-10 | 2.83M shares derived: sum of 3 quarters · filed 2023-08-10 | 5.90M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 550.67K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-22 | 798.12K shares derived: sum of 2 quarters · filed 2023-05-22 | 3.86M shares derived: sum of 3 quarters · filed 2023-05-22 | 4.17M shares 10-K · filed 2023-05-22 |
| 2022-12-31 | 247.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-03 | 3.31M shares derived: sum of 2 quarters · filed 2023-02-03 | 3.62M shares 10-Q · filed 2023-02-03 | 5.03M shares derived: sum of 4 quarters · filed 2023-02-03 |
| 2022-09-30 | 3.06M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-04 | 3.38M shares 10-Q · filed 2022-11-04 | 4.78M shares derived: sum of 3 quarters · filed 2022-11-04 | 5.47M shares derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-06-30 | 311.07K shares 10-Q · filed 2022-08-05 | 1.72M shares derived: sum of 2 quarters · filed 2022-08-05 | 2.41M shares derived: sum of 3 quarters · filed 2022-08-05 | 2.66M shares derived: sum of 4 quarters · filed 2022-08-05 |
| 2022-03-31 | 1.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | 2.10M shares derived: sum of 2 quarters · filed 2022-06-08 | 2.35M shares derived: sum of 3 quarters · filed 2022-06-08 | 2.78M shares 10-K · filed 2022-06-08 |
| 2021-12-31 | 689.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-04 | 937.84K shares derived: sum of 2 quarters · filed 2022-02-04 | 1.37M shares 10-Q · filed 2022-02-04 | 3.61M shares derived: sum of 4 quarters · filed 2022-02-04 |
| 2021-09-30 | 248.33K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-05 | 680.31K shares 10-Q · filed 2021-11-05 | 2.92M shares derived: sum of 3 quarters · filed 2021-11-05 | 3.23M shares derived: sum of 4 quarters · filed 2021-11-05 |
| 2021-06-30 | 431.98K shares 10-Q · filed 2021-08-09 | 2.67M shares derived: sum of 2 quarters · filed 2021-08-09 | 2.98M shares derived: sum of 3 quarters · filed 2021-08-09 | 3.65M shares derived: sum of 4 quarters · filed 2021-08-09 |
| 2021-03-31 | 2.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | 2.55M shares derived: sum of 2 quarters · filed 2021-06-01 | 3.21M shares derived: sum of 3 quarters · filed 2021-06-01 | 4.84M shares 10-K · filed 2021-06-01 |
| 2020-12-31 | 311.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | 975.79K shares derived: sum of 2 quarters · filed 2021-02-16 | 2.60M shares 10-Q · filed 2021-02-16 | 2.80M shares derived: sum of 4 quarters · filed 2021-02-16 |
| 2020-09-30 | 664.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | 2.29M shares 10-Q · filed 2020-11-12 | 2.49M shares derived: sum of 3 quarters · filed 2020-11-12 | |
| 2020-06-30 | 1.63M shares 10-Q · filed 2020-08-12 | 1.82M shares derived: sum of 2 quarters · filed 2020-08-12 | ||
| 2020-03-31 | 195.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29 | 4.79M shares 10-K · filed 2020-06-29 | ||
| 2019-12-31 | 4.59M shares 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |